James Davis, PharmD, BCOP
@thisisJamesD
Followers
595
Following
2K
Media
49
Statuses
321
Malignant hematology pharmacist and affiliate assistant professor @MUSCHollings #lymphoma #myeloma opinions are my own
Charleston, SC
Joined May 2021
For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology. https://t.co/aV2rpKDtgI
@AlGarfall
0
18
29
#Myeloma Paper of the Day: Real-world study of bispecific T-cell engager safety & efficacy in systemic AL #amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac & renal response in 64% & 100%; CRS in 45% (all G 1/2): https://t.co/LRNoCnjUD7.
#mmsm
1
14
32
Dex for management of CRS assoc w/ talquetamab [GPRC5D-targeting bispecific antibody (bsAb)] in Pts w/ RRMM [Nov 3, 2025] McElwee et al. #ASH25 abs25-14627 PID 720 https://t.co/L0BCnUjue9
#mmsm #SuppOnc
0
3
6
10/ #ASH25 Abstract 720: 1st-line CRS Tx with dex in #MMsm bsAbs (McElwee @thisisJamesD et al) "Pocket dex": equal efficacy, way cheaper / simpler than toci, albeit >1 dose more likely. This makes outpt bsAb SUD *way* easier for pts. As I now say: #Downwithdex
#ExceptforCRS !
2
3
11
Safety of live-attenuated MMR vaccination in Pts w/ multiple myeloma receiving daratumumab after autologous stem cell transplantation (ASCT) [Nov 3, 2025] Davis et al. #ASH25 abs25-1551 https://t.co/fK1kkVUn3N
#mmsm #bmtsm #IDonc #ImmunoOnc
0
1
6
Designing a strong bridge to CAR-T cells with bispecifics https://t.co/06jpjH6xkE
#immunobiologyandimmunotherapy
1
9
32
How well do bsAbs work for patients with DLBCL who relapse after CAR T? depends on time to relapse post-CAR... ORR similar, however CR and OS were significantly lower in those with refractory/early relapsed disease. led by @heMEGirl_MD and #ReemKarmali
https://t.co/AkZ1rw1aul
0
14
75
1/ Thanks Larry (and all co-authors) and @AjHematology for this! RW data for a frequent q in my own #MMsm clinic, namely patients starting teclistamab disappointed by D30 results after hearing "Median time to 1st response 1.1 mo"... Can we predict delayed response conversion?
Great job leading this one @RahulBanerjeeMD D30 ALC is a significant predictor of delayed responses to Tec in RRMM for initial non-responders. American Journal of Hematology | https://t.co/RT7oxhYR07
@GKaurMD @AlGarfall @SurbhiSidanaMD @utswcancer
3
13
54
Excited to share our newesr manuscript! Great collab w/ US Myeloma Immunotherapy Consortium showing impact of Flu LD exposure on CAR-T outcomes! Need prospective studies to validate model but even more đź‘€ on personalized chemo dosing!
astctjournal.org
The Food and Drug Administration (FDA) approval of idecabtagene vicleucel (ide-cel), an autologous B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T), repres...
0
9
14
CAR T-cell therapy for the beast that is plasma cell leukemia #PCL. đź‘Ź led by Doug Sborov and team at @huntsmancancer
https://t.co/zkIEFxmRtc
0
21
56
#Myeloma Paper of the Day: Targeting w/ talquetamab as bridge to BCMA CAR-T shows no grade ≥3 CRS, 2% grade 3 ICANS & grade 1-2 talq unique toxicities, 71% ORR, post CAR-T 88% responded/54% CR, 2 grade ≥3 CRS, 1 grade 3 ICANS, 5% grade ≥3 infxns: https://t.co/GemPoeEe3h.
#mmsm
5
12
37
1/ As @End_myeloma has said so eloquently: "The only place where BCMA must come before GPRC5D is the dictionary." Talquetamab bridging before BCMA CAR-T in myeloma - short, very effective, and rapidly becoming my preferred approach for patients with aggressive #MMsm biology!
🎉Finally out🎉 Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity @BloodPortfolio
https://t.co/QjnrOamEFo
#mmsm
1
22
81
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal
nature.com
Blood Cancer Journal - Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
1
8
34
Want to know why those other countries have lower brand drugs prices than us ? They don't have PBMs. We are the ONLY country that uses PBMs. Insane
768
3K
16K
#Myeloma Paper of the Day: US Myeloma Immunotx Consortium teclistamab data: 54% CRS (1.4% G≥3), 11% ICANS (2.2% G≥3), 42% infxns, 53% ≥PR, 45% ≥VGPR, PFS 5.8 mos, 12-mo OS 61%; BCMA CAR w/in 9 mos, hi dz/ferritin, lymphopenia reduce benefit: https://t.co/czDaJ7PMjb.
#mmsm
1
11
22
Great @BloodCancerJnl RW data from US #MMsm consortium, led by @DimaDanai @leshune et al! BCMA bsAbs can work in BCMA-exposed. While we await better predictive tools, time & type of prior therapy matters: - ⬆️ PFS if > 9 months since prior BCMA - ⬇️ PFS if prior BCMA was bsAb
#Myeloma Paper of the Day: Patients w/ >8.7 mos between last exposure to prior BCMA-directed therapy & teclistamab have significantly improved median PFS w/ tec (8.1 mos, 95% CI: 4.6-11.7) vs. pts with <8.7 mos (2.5 ms, 95% CI: 1.1-5.7), p=0.001: https://t.co/GpXJt19PW7.
#mmsm
2
15
40
Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 | Journal of Clinical Oncology
ascopubs.org
Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase...
0
35
98
Outcomes of older patients (>/= 75) with RRMM treated with teclistamab. No significant difference in CRS, ICANS or ORR #mmsm #bmtsm #Osvolsky @BloodCancerJnl
0
8
24
Final dinner at #HOPA2025 with some of my favorite folks @kczmj @VictoriaNachar @tayweis @corper17 @j_snyder0132 @saraleidy_ #bringitonbacktoburgerville
1
3
23
1
5
15